BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

Benzinga · 1d ago
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.